Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREP-COVID: Hydroxychloroquine and Azithromycin for COVID-19 Prevention
NCT04344379Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Coronavirus Disease 2019 (COVID-19) comparing hydroxychloroquine, azithromycin and Placebo of hydroxychloroquine (3 arms). Primary endpoint: Prevention of SARS-CoV-2 contamination at 3 months. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquineazithromycin
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04344379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344379.